Skip to NavigationSkip to content

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023 - ref #GB000008

PharmaPoint: Irritable Bowel Syndrome - Global Drug Forecast and Market Analysis to 2023

Summary


Irritable Bowel Syndrome (IBS) is a common disorder characterized by abdominal discomfort associated with altered bowel function. Although IBS is not a life-threatening disorder, it has a considerable effect on patients’ quality of life (QOL). In terms of volume, the IBS market is a large, albeit naïve, one, with only a small number of pharmacotherapies indicated for the treatment of the disorder, and it is also characterized by significant unmet needs.

As of October 2014, there were four products indicated for IBS in the 7MM. These include the constipation-predominant IBS (IBS-C) therapies, Sucampo/Takeda/Abbott’s Amitiza (lubiprostone) and Ironwood/Actavis/Almirall/Astellas’ Linzess (linaclotide), and the diarrhea-predominant IBS (IBS-D) therapies, Prometheus’ Lotronex (alosetron) and Astellas’ Irribow (ramosetron). Antidepressants and antibiotics (mainly Salix/Alfa Wassermann/Norgine/Bama-Geve’s Xifaxan [rifaximin]), are also commonly used off-label to treat IBS. GlobalData anticipates that four new therapies have the potential to enter the IBS market during the 2013-2023 forecast period. This includes Furiex’s (Actavis’) eluxadoline and Menarini’s ibodutant for IBS-D, and Synergy’s plecanatide and AstraZeneca/Ardelyx’s tenapanor for IBS-C. In addition, Xifaxan is in development for IBS-D, and has the potential to gain a label expansion for this indication during the forecast period.

Highlights

Key Questions Answered

  1. What do physicians think about Ironwood/Actavis/Almirall/Astellas’ Linzess and what will be the impact in the IBS market following its launch in 2012 in the US and 2013 in the 5EU region?
  2. What will be the uptake of Salix/Alfa Wassermann/Norgine/Bama-Geve’s Xifaxan following its anticipated label-expansion for IBS-D and how will it impact the treatment paradigm for IBS?
  3. What is the significance of late-phase pipeline products for IBS and how will their launch shape the future treatment landscape in IBS?
  4. What are the significant unmet needs in the IBS market?
  5. What are the remaining opportunities in the IBS market?

Key Findings

  • The IBS market value will be driven by the increasing uptake of Ironwood/Actavis/Almirall/Astellas’ Linzess and its expected launch in all the major European markets and Japan, the anticipated label expansion of Salix/Alfa Wassermann/Norgine/Bama-Geve’s Xifaxan for IBS-D, the potential introduction of four pipeline drugs for the treatment of IBS, and the increasing prevalent cases of IBS.
  • The main corporate strategy trend in the IBS market is for companies to enter into partnerships for the successful co-development and co-marketing of products in the different global regions.
  • The most pressing unmet need in the IBS market is for the development of drugs with improved efficacy.

Scope

  • Overview of IBS, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
  • Annualized IBS therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the IBS market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of mid-stage pipeline drugs.
  • Analysis of the current and future market competition in the global IBS market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global IBS market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global IBS market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global IBS market from 2013-2023.
  • Organize sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Publisher: GlobalData
Date published: 31-Dec-14

Price: £ 7,853.57

You need to agree to the Terms and Conditions before placing your order

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches